Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 169 - 176 of 12038 results
Calling All De-Regulators: FTC Issues Request for Public Comment on Reducing Anti-Competitive Regulatory Barriers
April 15, 2025| Alert| Viewpoint
Regulation, Enforcement, and Associated Challenges: Part II
April 15, 2025| Blog| Viewpoint
401k Plan Sponsor Questions Most Forget to Ask
April 15, 2025| News
'Continuing the Trend': Mintz Tops $700M in Revenue, Sees PEP Surge 22.2%
April 14, 2025| News
HHS Restructuring and Workforce Reductions – Key Implications for the Health Care Industry
April 14, 2025| Blog| Viewpoint
Federal Energy Policy Update: A Tumultuous Start to 2025
April 14, 2025| News
OMB Issues New Guidance for the Federal Government’s Use of AI, and President Trump Signs EO for AI Data Centers — AI: The Washington Report
April 11, 2025| Article| Viewpoint
Arbitration of SEP Disputes—A Growing Trend?
April 11, 2025| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|